This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
AZN's Bladder Cancer sBLA for Imfinzi Gets FDA's Priority Tag
by Zacks Equity Research
FDA grants priority review to AZN's sBLA seeking expanded use of Imfinzi for muscle-invasive bladder cancer.
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy
by Zacks Equity Research
Protara stock surges 70% as investigational cell therapy, TARA-002, shows superior six-month efficacy in phase II bladder cancer study.
5 Low Price-to-Sales Winners to Maximize Your Investment Gains
by Rajani Lohia
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like AGR, PCB, FIHL, GBX and PFE hold promise.
Zacks.com featured highlights Urban Outfitters, Maplebear, Pfizer and Alcoa
by Zacks Equity Research
Urban Outfitters, Maplebear, Pfizer and Alcoa have been highlighted in this Screen of The Week article.
Pfizer Stock Falls 8% in a Month: Should You Buy the Dip?
by Kinjel Shah
Investors with a long-term horizon may consider buying PFE stock at its present attractive valuation.
FDA Accepts Roche's Columvi sBLA for Expanded Use in Lymphoma
by Zacks Equity Research
The FDA accepts RHHBY's sBLA seeking the label expansion of Columvi to include the treatment of second-line R/R DLBCL for review.
Looking for Earnings Beat? Buy These 4 Top-Ranked Stocks
by Sanghamitra Saha
Top-ranked stocks Urban Outfitters, Maplebear, Pfizer and Alcoa are likely to beat on the bottom line in their upcoming releases.
Merck's ADC Drug Gets FDA Breakthrough Therapy Tag in NSCLC
by Zacks Equity Research
This is the first breakthrough therapy designation granted to MRK's sacituzumab tirumotecan in the United States.
PCRX Receives New Patent for Lead Pain Drug Exparel in the US
by Zacks Equity Research
The U.S. Patent and Trademark Office grants a new patent to protect the chemical composition of Pacira's lead pain-management drug, Exparel.
ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD
by Zacks Equity Research
Intra-Cellular submits an sNDA to the FDA, seeking the label expansion of Caplyta to treat MDD in adults as an adjunctive therapy to antidepressants.
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion
by Zacks Equity Research
NVS is all set to strengthen its neuroscience pipeline with the addition of PTCT's Huntington's disease drug.
PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy
by Zacks Equity Research
Purple Biotech stock surges 150.4% on reporting superior efficacy data from the mid-stage study of its combo therapy on pancreatic cancer patients.
NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals
by Zacks Equity Research
Novocure stock soars 49% as the late-stage study of TTFields therapy for treating pancreatic adenocarcinoma meets the primary endpoint of overall survival.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
5 Low Price-to-Book Value Stocks to Buy in December
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. GM, SEM, AXS, ZIM and PFE are some such stocks.
Zacks.com featured highlights Tyson Foods, AXIS Capital, Pfizer and General Motors
by Zacks Equity Research
Tyson Foods, AXIS Capital, Pfizer and General Motors have been highlighted in this Screen of The Week article.
4 Best Value Stocks to Invest in This December for Strong Returns
by Sumit Singh
Value investing is essentially about selecting stocks that are cheap but fundamentally sound. TSN, AXS, PFE & GM boast a low P/CF ratio.
RDY Launches Loqtorzi Biosimilar in India for Nasopharyngeal Carcinoma
by Zacks Equity Research
Dr. Reddy's launches Loqtorzi biosimilar in India under the brand name Zytorvi for treating adults with recurrent or metastatic nasopharyngeal carcinoma.
EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer
by Zacks Equity Research
Novartis wins EC approval for Kisqali in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence.
Pfizer (PFE) Down 9.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study
by Zacks Equity Research
Outlook Therapeutics stock tanks 65% as ONS-5010 fails to meet the pre-specified non-inferiority endpoint at week 8 in the 90-day NORSE EIGHT study for wet AMD.
APLT Stock Plunges 77% After FDA Issues CRL for Galactosemia Drug NDA
by Zacks Equity Research
Applied Therapeutics stock plummets 77% after the FDA issues a CRL for the company's NDA seeking approval for govorestat to treat classic galactosemia.
Are Investors Undervaluing Pfizer (PFE) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should You Buy More Shares of Your Loser Stocks?
by Tracey Ryniec
Intel, Disney and 3 others have struggled the last 5 years. Should long-time investors double down?